McKesson Corporation Reports 23% Revenue Growth in Q1 Fiscal 2026, Completes Major Acquisitions

McKesson Corporation reported significant financial results for the first quarter of fiscal 2026, ending June 30, 2025, with revenues reaching $97.8 billion, a 23% increase from $79.3 billion in the same period last year. The company's gross profit rose to $3.3 billion, up 4% from $3.2 billion, while net income attributable to McKesson Corporation decreased to $784 million, or $6.25 per diluted share, compared to $915 million, or $7.00 per diluted share, in the prior year. The decline in profitability was attributed to increased operating expenses and a provision for bad debts related to the bankruptcy of Rite Aid Corporation.

The company experienced notable changes in its operational landscape, including the completion of two major acquisitions: an 80% controlling interest in PRISM Vision Holdings for $874 million and a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures for $2.5 billion. These acquisitions are expected to enhance McKesson's capabilities in the U.S. Pharmaceutical segment. Additionally, McKesson announced plans to separate its Medical-Surgical Solutions segment into an independent company, reflecting a strategic shift aimed at optimizing its business structure.

Operationally, McKesson's U.S. Pharmaceutical segment saw revenues increase by 25% to $90 billion, driven by higher volumes from retail national account customers and growth in specialty pharmaceuticals. The Prescription Technology Solutions segment also reported a 16% revenue increase, while the Medical-Surgical Solutions and International segments experienced modest growth of 2% and 1%, respectively. The company’s total operating expenses rose by 6% to $2.2 billion, influenced by higher costs associated with the recent acquisitions and a significant provision for bad debts.

In terms of financial health, McKesson's cash and cash equivalents decreased to $2.4 billion from $5.7 billion at the end of the previous fiscal year. The company reported a total debt of $7.8 billion, up from $5.7 billion, primarily due to new debt issued to finance acquisitions. The debt-to-capital ratio improved to 115.9% from 125.3%, indicating a stronger capital structure. Looking ahead, McKesson anticipates continued growth driven by its strategic acquisitions and operational efficiencies, although it remains cautious about potential impacts from ongoing opioid-related litigation and market conditions.